Efficacy of Propranolol Treatment to Prevent Melanoma Progression

Stage IB Skin Melanoma Clinical Trial

Official title: Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial

Status Suspended

Clinical Trial Summary

Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies compared groups of patients diagnosed with primary melanoma and treated with betablockers for another indication to patients who never received betablockers. In these three studies, the outcome of the disease is significantly better for people under betablocker treatment with a decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate the efficacy and the tolerability of an adjuvant treatment with propranolol for patients suffering from a primary melanoma with a high risk of recurrence.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Melanoma
• Skin Neoplasms
• Stage IB Skin Melanoma
• Stages II Skin Melanoma
• Stages III Skin Melanoma

• NCT number: NCT01988831
• Study type: Interventional
• Source: University Hospital, Geneva
• Status: Suspended
• Phase: Phase 2
• Start date: June 2016
• Completion date: March 2022